The global epinephrine auto-injectors market is estimated to reach USD 2,228.0 million in 2024, with projections indicating a substantial increase to USD 3,394.4 million by 2034. This growth represents a compound annual growth rate (CAGR) of 4.3% over the forecast period, reflecting the rising demand for effective allergy treatment solutions.
The primary driver of this market growth is the increasing prevalence of drug-related and environmental allergies worldwide. Food allergies, particularly those triggered by peanuts, shellfish, and tree nuts, have seen a significant rise and are recognized as major life-threatening conditions, especially among children. Additionally, severe allergic reactions caused by insect stings and medications, such as antibiotics and aspirin, have further escalated the need for immediate treatment options.
Epinephrine auto-injectors provide a critical lifeline in managing anaphylactic reactions, offering fast and effective intervention that can prevent fatal outcomes. As awareness of these allergies grows, the demand for epinephrine auto-injectors is expected to rise, making them an essential component of emergency allergy management.
The market is also witnessing advancements in technology and product design, enhancing the usability and accessibility of epinephrine auto-injectors for both patients and caregivers. These innovations aim to improve patient adherence to allergy management plans and ensure timely administration during emergencies.
This upward trajectory is fueled by the increasing demand for epinephrine auto-injectors, driven by notable advancements in syringe and injector technologies. Responding to evolving clinical and patient needs, manufacturers within the industry have demonstrated significant innovation, contributing significantly to the burgeoning market.
One of the driving forces behind this growth is the escalating prevalence of allergies worldwide. Individuals facing allergic reactions to dust, insect bites, venom, food, and food additives have significantly contributed to the expanding market for epinephrine auto-injectors. As a result, the industry is witnessing a surge in opportunities and a widening consumer base.
Furthermore, vendor investments in research and development initiatives have played a pivotal role in shaping key trends and opportunities within the Global Epinephrine Auto-Injectors Industry. A noteworthy development includes the creation of chlorofluorocarbon-free epinephrine auto-injector inhalers using hydrofluoroalkanes as propellants. This environmentally conscious approach not only aligns with global sustainability goals but also propels the industry into a new era of innovation.
However, excessive use of epinephrine can lead to adverse side effects such as cardiac arrhythmia, pulmonary edema, vomiting, and brain hemorrhage, which may pose a challenge for the Global Epinephrine Auto-Injectors Industry.
During the forecast period, the regional market for epinephrine auto-injectors is expected to be driven by the increasing number of people suffering from various types of allergies, the availability of low-cost generic epinephrine auto-injectors, and the high adoption rate of epinephrine auto-injectors in the United States. The adoption trends in the epinephrine auto-injector market are also expected to contribute to its growth.
Epinephrine Auto-Injectors Market Key Takeaways:
- In the United States, the epinephrine auto-injectors market size is estimated to reach US$ 1.2 Billion by 2032, increasing at a CAGR of 4.7% through 2032.
- The epinephrine auto-injectors market share in the United Kingdom is expected to be worth US$ 132.9 Million by 2032, with a CAGR of 3.6% through 2032.
- China’s epinephrine auto-injectors market share is expected to reach US$ 233.7 Million by 2032, with a CAGR of 4.2% through 2032.
- The market share for epinephrine auto-injectors in Japan is expected to be valued at US$ 188.5 Million by 2032, expanding at a 3.3% annual rate through 2032.
- South Korea is expected to reach a market size of US$ 117.6 Million in epinephrine auto-injectors by 2032, with a CAGR of 2.8% through 2032.
- The epinephrine auto-injectors market’s Hospitals segment from the end user category is predicted to develop at a CAGR of 4.8% through 2032.
- Through 2032, the 0.3 mg sector in the epinephrine auto-injectors market’s dosage category will grow at a CAGR of 4.9%.
Epinephrine Auto-Injectors Market Competitive Landscape:
A new market research report on epinephrine auto-injectors says that Adamis Pharmaceuticals Corporation, Alk-Abello A/S, Impax Laboratories, Inc., Mylan N.V., and Antares Pharma is among the legacy player’s vendors.
The research offers a comprehensive competition analysis of these top competitors in the epinephrine auto-injectors market, including Global Epinephrine Auto-Injectors Industry growth, epinephrine auto-injectors market share, Global Epinephrine Auto-Injectors Industry adoption trends and important market strategies.
Recent Development in the Epinephrine Auto-Injectors Market:
- Antares Pharma (US) struck an arrangement with Lunatus Global Medical Supplies in August 2020. (Dubai). Antares will deliver packaged goods to Lunatus under this arrangement, and Lunatus will submit and get regulatory permission for XYOSTED in the UAE and Saudi Arabia, as well as promote, market, and distribute XYOSTED in these two countries.
- SHL Medical (Switzerland) bought Weibel CDS in March 2020. (Switzerland). The goal of this purchase was to increase SHL Medical’s capacity to develop more sophisticated medication delivery systems based on human-centered designs and functionality.
- Eli Lilly spent US$ 470 million and generated approximately 460 new jobs in Durham, NC in January 2020. With this extension, North Carolina’s Research Triangle Park gained a new state-of-the-art pharmaceutical production plant.
Epinephrine Auto-Injectors Market Key Segments:
By End-User:
- Hospitals
- Clinics
- Home Based
- Others
By Dosage:
- 0.15 mg
- 0.3 mg
- Others
By Age Group:
- 0-4 Years
- 5-14 Years
- 15-24 Years
- 25-49 Years
- 50-64 Years
- Above 65 Years
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
